| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | 3,501 | 5,876 | 5,458 | 5,481 |
| Net loss | -41,400 | -50,943 | -59,733 | -66,293 |
| Net unrealized gain (loss) on available-for-sale investments | 280 | -88 | 132 | 937 |
| Net comprehensive loss | -41,120 | -51,031 | -59,601 | -65,356 |
| Net loss per share, basic (in dollars per share) | -0.19 | -0.23 | -0.28 | -0.32 |
| Net loss per share, diluted (in dollars per share) | -0.19 | -0.23 | -0.28 | -0.32 |
| Weighted-average number of shares used in computing net loss per share, basic (in shares) | 222,038,680 | 218,929,548 | 215,358,619 | 209,188,551 |
| Weighted-average number of shares used in computing net loss per share, diluted (in shares) | 222,038,680 | 218,929,548 | 215,358,619 | 209,188,551 |
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)